CJC-1295
PeptideA synthetic peptide that stimulates growth hormone release by binding to GHRH receptors. Used for muscle growth, fat loss, and recovery. Often combined with ipamorelin.
Evidence comparisons not yet run for these claims.
Expert Consensus
Evidence Summary
Significant limitations exist across the board. There are no clinical trials in this dataset evaluating CJC-1295's effects on body composition, growth hormone levels, recovery, or any other outcome. The sole study provides no quantitative data, no control group, and no verified health outcomes — only anecdotal, self-reported accounts from an unspecified online population. The long-term safety profile of CJC-1295, potential hormonal side effects, optimal dosing, and interactions with other substances remain entirely uncharacterized by the research reviewed here. Anyone considering this supplement should be aware that the evidence base, at least as represented here, does not support evidence-based decision-making.
Read full evidence summary →Top studies
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
Expert Mentions
All 9 mentions“it's worse if you drink alcohol if you have wine so I had wine and then I injected and I felt like I was on fire”
The burning sensation from CJC-1295 is worse if you have consumed alcohol beforehand.
“it's worse if you drink alcohol if you have wine so I had wine and then I injected and I felt like I was on fire”
The burning sensation from CJC-1295 is worse if you have consumed alcohol beforehand.
Shop CJC-1295
View on Amazon
As an Amazon Associate, Abstraction Health earns from qualifying purchases at no extra cost to you.
Key findings
- ·Only one study was identified, and it was a netnography (qualitative analysis of online discussions), not a clinical trial.
- ·The study focused exclusively on female use patterns and self-reported experiences with CJC-1295 in online communities.
- ·No quantitative outcomes, population sizes, or specific findings were available from the study.
Evidence gaps
- ·There are no clinical trials in the reviewed literature measuring the actual physiological effects of CJC-1295 in humans, including impacts on growth hormone levels, body composition, or recovery.
- ·The safety profile of CJC-1295 — including hormonal side effects, long-term risks, and drug interactions — is completely unaddressed by the available research.
- ·Effective dosing, timing, and population-specific responses (e.g., by sex, age, or health status) have not been studied in the provided evidence base.